Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Diseases
Launched by RIGSHOSPITALET, DENMARK · Jul 10, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on finding new biological markers, or "biomarkers," that can help doctors better understand and treat patients with inflammatory rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and gout. The goal is to identify these biomarkers to improve how quickly and accurately these diseases are diagnosed, predict how they will progress, and determine which treatments will work best for each individual patient. Currently, about 30-40% of patients do not respond well to existing treatments, so this research aims to enhance personalized care for these conditions.
To participate in this study, individuals must be at least 18 years old and either have been diagnosed with or suspected to have one of the inflammatory rheumatic diseases mentioned. Participants will provide a blood sample and share information about their health and lifestyle. The study is designed to collect data over time, allowing researchers to analyze how different biomarkers relate to treatment effectiveness and side effects. The research is ethically approved, and all participants will give informed consent before joining. This study represents an important step towards tailored treatments that could lead to better outcomes for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with or suspected for the following diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) or other inflammatory rheumatic diseases, connective tissue disorders or gout
- • Aged 18 year or older
- • Able to give informed consent
- Exclusion Criteria:
- • None
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aalborg, , Denmark
Aarhus, , Denmark
Copenhagen, , Denmark
Copenhagen, , Denmark
Hjørring, , Denmark
Køge, , Denmark
Odense, , Denmark
Randers, , Denmark
Svendborg, , Denmark
Sønderborg, , Denmark
Vejle, , Denmark
Patients applied
Trial Officials
Merete L Hetland, Professor
Principal Investigator
Rigshospitalet, Glostrup, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials